Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-Blind, Randomized, Placebo-Controlled, Multi-Centre Study to Investigate the Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease With Evidence of Mucosal Ulceration

Next Previous
Trial Profile

Double-Blind, Randomized, Placebo-Controlled, Multi-Centre Study to Investigate the Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease With Evidence of Mucosal Ulceration

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Filgotinib (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms FITZROY
  • Sponsors Galapagos NV

    • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 01 Nov 2017 Results of post-hoc analysis assessing effect of disease duration and location on primary end point, presented at the 25th United European Gastroenterology Week.
    • 01 Nov 2017 Results of post-hoc analysis assessing correlation between histologic and endoscopic disease activity, presented at the 25th United European Gastroenterology Week.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top